Trajan Group (TRJ) investor relations material

Business and portfolio

• Founded in 2011; develops and manufactures analytical and life science products for biological, food and environmental sample analysis, with ~600 FTE across four continents.

• Components & Consumables contribute 70% of revenue, Capital Equipment 30%, and Disruptive Technologies less than 1%.

• Technologies support decentralised, personalised, data-based healthcare; products serve clinical, food safety, pharmaceutical and environmental markets.

Global footprint and operating model

• Ten operating locations and seven global manufacturing sites; more than 8,000 SKUs and channels spanning OEM, distributors and direct sales.

• More than 95% of revenue and 61% of staff are outside Australia; manufacturing footprint enables in-region production as needed.

• Acquisition integration is staged, with efficiencies and momentum built while retaining talent; nEBITDA is the preferred metric for underlying business health.

FY26 financial performance

• Revenue $161.4M, down 3.1% vs PCP; nEBITDA $13.2M, down 14.7%; pro forma gross margin 38.9%, down 0.8 pts.

• Operating NPATA $2.2M, up 191.3% vs PCP; cash $12.6M, up 6.5%; net debt $34.6M, up 17.0%.

• H2 nEBITDA rose to $8.1M from H1 $5.0M, up 61.8%; H2 nEBITDA was $10.5M at H1 foreign exchange rates.

• H2 pro forma gross margin reached 40.6%, up 3.2 pts vs H1, and 41.2% at H1 foreign exchange rates; AUD appreciation affected H2 revenue by ~$5.0M.